Morphine extended release - Egalet

Drug Profile

Morphine extended release - Egalet

Alternative Names: AD ER morphine; ARYMO; ARYMO™ ER; EG-P113; EG-PO66 Morphine; Egalet Morphine; Egalet-001; Opioid 1

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Egalet
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Pain

Most Recent Events

  • 09 Jan 2017 Registered for Pain in USA (PO)
  • 09 Jan 2017 Egalet announces intention to launch morphine extended release in first quarter of 2017
  • 13 Oct 2016 The US FDA extends PDUFA date of 14 Oct 2016 for NDA review for use in Pain (PO) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top